MITOZOLOMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H7ClN6O2
Molecular Weight	242.622
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1=C2N=NN(CCCl)C(=O)N2C=N1

InChI

InChIKey=QXYYYPFGTSJXNS-UHFFFAOYSA-N

InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15)

HIDE SMILES / InChI

Molecular Formula	C7H7ClN6O2
Molecular Weight	242.622
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3524827 | https://www.ncbi.nlm.nih.gov/pubmed/2714350

Mitozolomide is an antineoplastic agent patented by May and Baker Ltd for cancer treatment. Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.

Originator

Approval Year

PubMed

Title	Date	PubMed
Transient transfection of a synthetic hammerhead ribozyme targeted against human MGMT gene to cells in culture potentiates the genotoxicity of the alkylation damage induced by mitozolomide.	1999 Apr	10355819
Recombinant adeno-associated virus-mediated expression of O6-alkylguanine-DNA-alkyltransferase protects human epithelial and hematopoietic cells against chloroethylating agent toxicity.	1999 Jan 20	10022554
Ribozyme and free alkylated base: a dual approach for sensitizing Mex+ cells to the alkylating antineoplastic drug.	2000 Jun	10880022
Synthesis and antibacterial activity of dual-action agents of a beta-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide.	2002 Apr	11960667
Antitumor imidazotetrazines. 41. Conjugation of the antitumor agents mitozolomide and temozolomide to peptides and lexitropsins bearing DNA major and minor groove-binding structural motifs.	2002 Dec 5	12459014
The sensitivity of MCF10A breast epithelial cells to alkylating drugs is enhanced by the inhibition of O6-methylguanine-DNA methyltransferase transcription with a synthetic double strand DNA oligonucleotide.	2002 Jun	12160326
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.	2003 Apr 7	12671695
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.	2003 Aug 4	12888809
Pyrrolo[2,1-d][1,2,3,5]tetrazine-4(3H)-ones, a new class of azolotetrazines with potent antitumor activity.	2003 May 29	12735982
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.	2004 Dec 8	15588281
Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.	2004 Sep 13	15365562
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.	2010	20357518

Patents

Sample Use Guides

In Vivo Use Guide

100 mg/m^2 every 6 weeks.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:30:05 GMT 2023` Edited by `admin` on `Fri Dec 15 16:30:05 GMT 2023`
Record UNII	E3U7286V3W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MITOZOLOMIDE

Official Name

English

mitozolomide [INN]

Common Name

English

3-(2-CHLOROETHYL)-3,4-DIHYDRO-4-OXOIMIDAZO(5,1-D)-AS-TETRAZINE-8-CARBOXAMIDE

Common Name

English

NSC-353451

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C902